Beacon Investment Advisory Services Inc. Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Beacon Investment Advisory Services Inc. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,401 shares of the biopharmaceutical company’s stock after selling 235 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,210,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Souders Financial Advisors lifted its position in shares of Alnylam Pharmaceuticals by 1.0% during the second quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after buying an additional 36 shares during the last quarter. Huntington National Bank raised its position in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Lindbrook Capital LLC raised its position in shares of Alnylam Pharmaceuticals by 11.1% in the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 57 shares during the last quarter. V Square Quantitative Management LLC raised its position in shares of Alnylam Pharmaceuticals by 21.9% in the 2nd quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 60 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Alnylam Pharmaceuticals by 54.2% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 91 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,370 shares of company stock valued at $2,100,703. 1.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ALNY. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Bank of America increased their price objective on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $198.00 to $370.00 in a research report on Friday, August 16th. Scotiabank increased their price objective on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. Finally, Chardan Capital reiterated a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $253.01 on Tuesday. The stock has a market capitalization of $32.63 billion, a price-to-earnings ratio of -96.57 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The firm’s 50 day simple moving average is $271.07 and its 200-day simple moving average is $242.32. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter in the prior year, the company earned $1.15 earnings per share. The business’s revenue for the quarter was down 33.3% compared to the same quarter last year. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.